Transformingthe treatment of chronic disease.
Enhancingthe body’s healing response.
Rebalancingthe immune system.
Discoveringthe power of VSELs.
Leveragingexperience in cell therapy.
NeoStem - Transforming the Treatment of Chronic Disease
NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
News + EventsNeoStem Expands Treg International Patent Portfolio with Granting of Patent in Japan Feb. 4, 2014 — Learn More
NeoStem Welcomes David Altarac, M.D., as Vice President, Regulatory Affairs Jan. 28, 2014 — Learn More
NeoStem Expands Patent Portfolio with New US and European Patent Allowances Jan. 6, 2014 — Learn More
We are pleased to introduce Dr. Douglas Losordo, Chief Medical Officer of NeoStem, Inc. Dr. Losordo is a well-known cardiologist and an expert in stem cell biology. He understands first-hand how far adult stem cell science has progressed, as well as how far we still need to go. The following interview with Dr. Losordo shares some of his insights on the field, spreading knowledge about adult stem cells and how the world can get excited about a future where cell therapies will make a meaningful difference in the lives of millions.
This month I had the pleasure of announcing that NeoStem has completed enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blind placebo-controlled Phase 2 clinical trial testing the company’s lead product candidate, AMR-001, an autologous adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI). The infusion of the target population of 160 patients took place at 60 medical centers across the United States. We expect data readout in the third quarter of 2014.